MedPath

Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)

Phase 2
Terminated
Conditions
Movement Disorders
Antipsychotic Agents
Akathisia, Drug-Induced
Interventions
Drug: Anticholinergic agents or propanolol
Drug: Placebo
Drug: Preladenant
Drug: Haloperidol
First Posted Date
2008-06-09
Last Posted Date
2018-11-07
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
46
Registration Number
NCT00693472

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Phase 3
Withdrawn
Conditions
Prostate Cancer
Interventions
Drug: odanacatib
Drug: placebo (unspecified)
First Posted Date
2008-06-06
Last Posted Date
2016-08-12
Lead Sponsor
Merck Sharp & Dohme LLC
Registration Number
NCT00691899

A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)

Phase 2
Terminated
Conditions
Macular Edema
Interventions
Drug: triamcinolone acetonide
First Posted Date
2008-06-06
Last Posted Date
2015-11-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
2
Registration Number
NCT00692614

A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

Phase 3
Withdrawn
Conditions
Breast Cancer
First Posted Date
2008-06-06
Last Posted Date
2016-08-12
Lead Sponsor
Merck Sharp & Dohme LLC
Registration Number
NCT00692458

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Navarixin
Drug: Placebo
First Posted Date
2008-06-03
Last Posted Date
2019-01-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
19
Registration Number
NCT00688467

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Phase 2
Terminated
Conditions
Hepatitis C, Chronic
Hepacivirus
Interventions
Biological: Narlaprevir
Biological: Boceprevir
Biological: Peginterferon alfa-2b
Drug: Ribavirin
Other: Blood/Plasma Collection
First Posted Date
2008-06-03
Last Posted Date
2018-09-11
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1954
Registration Number
NCT00689390

A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)

Phase 2
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: Atorvastatin calcium
Drug: MK-6213
Drug: Placebo for Atorvastatin 20 mg
Drug: Placebo for MK-6312 160 mg
First Posted Date
2008-05-30
Last Posted Date
2019-01-14
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
334
Registration Number
NCT00687271

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

Phase 2
Completed
Conditions
Breast Neoplasm
Interventions
Drug: Pegylated Liposomal Doxorubicin
Drug: Docetaxel
Drug: Trastuzumab
First Posted Date
2008-05-30
Last Posted Date
2018-07-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
27
Registration Number
NCT00687440

Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)

Phase 4
Terminated
Conditions
Spondylitis, Ankylosing
SpA
Interventions
Procedure: PDUS
Drug: Infliximab
First Posted Date
2008-05-30
Last Posted Date
2017-03-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
7
Registration Number
NCT00686894

Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)

Phase 2
Completed
Conditions
HIV
HIV Infections
Interventions
Drug: Vicriviroc maleate
First Posted Date
2008-05-30
Last Posted Date
2020-12-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
79
Registration Number
NCT00686829
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy